Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Homochlorcyclizine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 known ✓ | P35462 | 5/20 | 0.97 |
| ▸ | CHRM2 known ✓ | P08172 | 4/20 | 0.97 |
| ▸ | ADRA2A known ✓ | P08913 | 4/20 | 0.97 |
| ▸ | KCNH2 known ✓ | Q12809 | 4/20 | 0.97 |
| ▸ | CHRM1 known ✓ | P11229 | 3/20 | 0.97 |
| ▸ | DRD1 known ✓ | P21728 | 3/20 | 0.97 |
| ▸ | SLC6A3 known ✓ | Q01959 | 3/20 | 0.97 |
| ▸ | ADRA1A known ✓ | P35348 | 3/20 | 0.97 |
| ▸ | OPRM1 known ✓ | P35372 | 3/20 | 0.97 |
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.97 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.97 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.97 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.85 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.68 |
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 0.68 |
| ▸ | HTR2B known ✓ | P41595 | 2/20 | 0.68 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.68 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 0.68 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.68 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Homochlorcyclizine SCHEMBL1977999 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNAKDM4EMEN1KMT2A | |
| Homochlorcyclizine SCHEMBL30402 | 0.98 | DRD3 (1.00) | SMN1; SMN2LMNAKDM4EMEN1KMT2A | |
| Chlorcyclizine SCHEMBL321657 | 0.94 | CYP2D6 (1.00) | SMN1; SMN2LMNAKDM4EMEN1KMT2A | |
| Chlorcyclizine SCHEMBL12157065 | 0.92 | KCNH2 (1.00) | SMN1; SMN2LMNAKDM4EMEN1KMT2A | |
| Chlorcyclizine SCHEMBL4383 | 0.92 | KCNH2 (1.00) | SMN1; SMN2LMNAKDM4EMEN1KMT2A | |
| Chlorcyclizine SCHEMBL16769331 | 0.92 | KCNH2 (1.00) | SMN1; SMN2LMNAKDM4EMEN1KMT2A | |
| Chlorcyclizine SCHEMBL13724147 | 0.92 | KCNH2 (1.00) | SMN1; SMN2LMNAKDM4EMEN1KMT2A | |
| SCHEMBL2056217 | 0.86 | CHRM2 (0.86) | SMN1; SMN2LMNAKDM4EMEN1KMT2A | |
| SCHEMBL7668121 | 0.84 | CHRM2 (0.83) | SMN1; SMN2LMNAKDM4EMEN1KMT2A | |
| Cyclizine SCHEMBL97825 | 0.84 | CYP2D6 (0.96) | SMN1; SMN2LMNAKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 541 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10273252-B2 | Substituted dihydropyrrolopyrazole derivative | UBE INDUSTRIES, LTD. (JP) | 2019-04-30 | — | — | US | claimed |
| US-20180186818-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2018-07-05 | — | — | US | claimed |
| EP-3309163-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | UBE Industries, Ltd. (JP) | 2018-04-18 | — | — | EP | claimed |
| CN-107735401-A | Substituted Dihydropyrrolopyrazole Derivatives | 宇部兴产株式会社 | 2018-02-23 | — | — | CN | claimed |
| US-20100239690-A1 | COMPOSITION FOR ORAL CAVITY AND SKIN | NODA SATOSHI | 2010-09-23 | — | — | US | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-5288503-A | WATER-PERMEABLE DIFFUSION BARRIER OF POLYVINYL ALCOHOL | SRCHEM INCORPORATED (US) | 1994-02-22 | — | — | US | claimed |
| US-5260066-A | Cryogel bandage containing therapeutic agent | SRCHEM INCORPORATED (US) | 1993-11-09 | — | — | US | claimed |
| EP-0189861-A2 | Percutaneous absorption accelerator for ionic water-soluble medicine | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1986-08-06 | — | — | EP | claimed |
| EP-0079545-A1 | Benzimidazole derivatives, process for the preparation thereof and pharmaceutical composition containing the same | KANEBO, LTD. (JP) | 1983-05-25 | — | — | EP | claimed |
| JP-11106354-A | — | — | None | — | — | JP | disclosed |
| US-12629379-B2 | Pharmaceutical composition for preventing, suppressing, or treating symptom associated with allergic reaction | NIPPON CHEMIPHAR CO., LTD. (JP) | 2026-05-19 | — | — | US | disclosed |
| US-20260000678-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH PSEUDO-ALLERGIC REACTION | TAKASAKI UNIV OF HEALTH AND WELFARE (JP) | 2026-01-01 | — | — | US | disclosed |
| US-20250197401-A1 | PURINONE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2025-06-19 | — | — | US | disclosed |
| US-12304913-B2 | Dihydropyrrolopyrazole derivative | UBE INDUSTRIES, LTD. (JP) | 2025-05-20 | — | — | US | disclosed |
| US-4603130-A | ANTIHISTAMINES | KANEBO, LTD. (JP) | 1986-07-29 | — | — | US | disclosed |
| EP-0079545-B1 | BENZIMIDAZOLE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KANEBO, LTD. (JP) | 1986-05-21 | — | — | EP | disclosed |
| EP-0123962-A2 | Benzimidazole derivative, process for the preparation thereof and pharmaceutical composition | KANEBO, LTD. (JP) | 1984-11-07 | — | — | EP | disclosed |
| US-4430343-A | ANTIHISTAMINES | KANEBO, LTD. (JP) | 1984-02-07 | — | — | US | disclosed |
| EP-0079545-A1 | Benzimidazole derivatives, process for the preparation thereof and pharmaceutical composition containing the same | KANEBO, LTD. (JP) | 1983-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12304913-B2 | Dihydropyrrolopyrazole derivative | CBR3, SLC13A3, CYP3A5 | DRD3 17/4885CHRM2 955/4885ADRA2A 267/4885 |
| US-12629379-B2 | Pharmaceutical composition for preventing, suppressing, or treating symptom associated with allergic reaction | HRH2, HRH4, HRH1 | DRD3 2640/4885CHRM2 652/4885ADRA2A 113/4885 |
| US-20260000678-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH PSEUDO-ALLERGIC REACTION | TRPV1, TRPV4, TRPV5 | DRD3 3321/4885CHRM2 790/4885ADRA2A 565/4885 |
| US-20250197401-A1 | PURINONE DERIVATIVE | BTK, KIT, SYK | DRD3 609/4885CHRM2 2961/4885ADRA2A 1737/4885 |
| US-10273252-B2 | Substituted dihydropyrrolopyrazole derivative | QDPR, CYP11B2, CYP4F3 | DRD3 251/4885CHRM2 2031/4885ADRA2A 557/4885 |
| US-20180186818-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | QDPR, CYP11B2, CYP4F3 | DRD3 251/4885CHRM2 2031/4885ADRA2A 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.